Evoq Remedies (BOM:543500) Cyclically Adjusted PS Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543500 Evoq Remedies Ltd BOM:543500
58 GF Score
Price ₹1.62
GF Value ₹12.83
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Evoq Remedies Cyclically Adjusted PS Ratio?

Evoq Remedies does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evoq Remedies  (BOM:543500) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evoq Remedies Cyclically Adjusted PS Ratio Related Terms


Evoq Remedies Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Evoq Remedies's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evoq Remedies Cyclically Adjusted PS Ratio Chart

Evoq Remedies Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Evoq Remedies Semi-Annual Data
Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:543500 vs MCK, COR, CAH: Cyclically Adjusted PS Ratio Comparison

For the Medical Distribution subindustry, Evoq Remedies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evoq Remedies Cyclically Adjusted PS Ratio vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Evoq Remedies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evoq Remedies's Cyclically Adjusted PS Ratio falls into.


BOM:543500
58GF Score
Evoq Remedies Ltd BOM:543500
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evoq Remedies Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evoq Remedies does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Is Evoq Remedies (BOM:543500) Overvalued in 2026?

Based on GuruFocus' analysis, Evoq Remedies stock appears to be undervalued. The current stock price of ₹1.62 is trading 87.4% below its estimated GF Value™ of ₹12.83. GuruFocus considers Evoq Remedies to be Possible Value Trap.

Key valuation signals for BOM:543500:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹12.83 vs. price of ₹1.62 (87.4% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the BOM:543500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evoq Remedies Business Description

Address Science City Road, A-1106, Empire Business Hub, Near AUDA Water Tank, Sola, Ahmedabad, GJ, IND, 380060
Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading, and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections, and others. It operates in a single segment that is Pharmaceutical Trading.
58GF Score

Get the complete analysis for BOM:543500

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1.62
Price
₹12.83
GF Value